Article thumbnail

Survival benefits of lung cancer patients undergoing laser and brachytherapy.

By Tae Won Jang, Glen Blackman and Jeremy J. George


We aimed to compare the duration of survival among subjects receiving brachytherapy (BT) in combination with Nd:YAG laser therapy (LT), and those receiving LT or BT alone. The medical records of subjects who received endobronchial treatment for unresectable tracheobronchial malignancies between January 1997 and December 1999 in a single center were reviewed retrospectively. A total of 80 patients were evaluated. The overall symptomatic response rate after treatment was 86.5%. Median survival durations for the LT, BT, and combined therapy (CT) group were 111, 115, and 264 days, respectively. The survival duration was significantly longer in the CT group than in the BT group (p=0.0078), but the difference was not statistically significant between the CT and the LT group. The bronchoscopic finding of endobronchial polypoid lesion was associated with a longer survival time than extraluminal with compression type (p=0.0023) by univariate analysis. Other factors associated with the better prognosis included hemoglobin > or = 12.5 g/dL, serum albumin level > or = 37 g/L, and BT dose > or = 15 Gy at 1 cm distance. Of these factors, specific bronchoscopic findings, serum albumin level, CT modality, and dose of BT retained statistical significance in multivariate analysis. In conclusion, combined LT and BT is associated with increased patient survival compared with BT alone. Combined therapy may improve survival time in selected patients with endobronchial malignancies

Topics: Research Article
Publisher: Korean Academy of Medical Sciences
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1980). A prospective randomized study of various irradiation and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung. Cancer
  2. (1991). and histopathologic correlates in bronchogenic carcinoma. A review of 1,045 bronchoscopic examinations. Chest
  3. (1985). Combined laser therapy and endobronchial radiotherapy for unresectable lung carcinoma with bronchial obstruction.
  4. (2000). Combined Nd-YAG laser/HDR brachytherapy versus Nd-YAG laser only in malignant central airway involvement: a prospective randomized study. Lung Cancer
  5. (1991). Complications associated with brachytherapy alone or with laser in the lung cancer. Chest
  6. (1992). Controversies in the nonsurgical treatment of stage III non-small cell cancer. Am Rev Respir Dis
  7. (1976). Design and analysis of randomized clinical trials requiring prolonged observation of each patient.
  8. (1989). Effect of radiation therapy on bronchial obstruction due to bronchogenic carcinoma. Chest
  9. (1998). Endobronchial high dose rate brachytherapy.
  10. (1998). Endobronchial laser treatment.
  11. (1975). Endobronchial metastasis.
  12. (1996). Endoscopic laser resection for tracheobronchial malignancy. Thorax
  13. (1986). Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced nonsmall cell lung cancer treated with combination chemotherapy.
  14. (1985). High dose intraluminal irradiation in recurrent endobronchial carcinoma. Chest
  15. (1998). High dose rate endobronchial brachytherapy: results and complications in 189 patients.
  16. (1993). High dose rate intraluminal irradiation in bronchogenic carcinoma: technique and results. Chest
  17. (1997). Local determinants of response to endobronchial high-dose rate brachytherapy in bronchogenic carcinoma. Chest
  18. (1996). Long term survival and symptom palliation in small primary bronchial carcinoma following treatment with intraluminal radiotherapy alone. Clin Oncol
  19. Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is
  20. (1986). Palliation of bronchogenic carcinoma with 198Au implantation using the fiberoptic bronchoscope. Preliminary report by the radiation therapy oncology group. Chest
  21. (1998). Predictive factors for late toxicity after endobronchial brachytherapy: a multivariate analysis.
  22. (1994). Prolonged survival after high-dose rate endobronchial radiation for malignant airway obstruction. Chest
  23. (1986). Prospective evaluation of a watch policy in patients with inoperable non-small cell cancer.
  24. (1972). Regression models and life tables (with discussion).
  25. (1993). Remote afterloading brachytherapy for the local control of endobronchial carcinoma.
  26. (1991). Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group experience.
  27. Survival of patients undergoing Nd:YAG laser therapy compared with Nd:YAG laser therapy and brachytherapy for malignant airway disease. Chest 1993; 103: 1028-31.Survival of Lung Cancer Patients Undergoing Laser and
  28. (1996). The national cancer data base report on lung cancer. Cancer
  29. (1992). Treatment of non-small cell lung cancer with external beam radiotherapy and high dose rate brachytherapy.
  30. (1990). YAG laser and brachytherapy in the management of inoperable bronchogenic carcinoma. Ann Thorac Surg